Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) announced its quarterly earnings results on Thursday. The basic materials company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.31), FiscalAI reports. Arcadia Biosciences had a negative net margin of 97.97% and a negative return on equity of 8.80%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $1.40 million.
Arcadia Biosciences Stock Performance
Shares of Arcadia Biosciences stock traded down $0.18 during trading on Thursday, hitting $1.52. 14,578 shares of the company’s stock were exchanged, compared to its average volume of 33,867. The stock has a market capitalization of $2.63 million, a price-to-earnings ratio of 0.60 and a beta of 0.57. The business has a 50-day simple moving average of $1.93 and a 200-day simple moving average of $2.95. Arcadia Biosciences has a 52-week low of $1.52 and a 52-week high of $6.71.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcadia Biosciences in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
About Arcadia Biosciences
Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.
Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.
Featured Stories
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
